Cargando…

Switching to second line MS disease-modifying therapies is associated with decreased relapse rate

BACKGROUND AND OBJECTIVES: While randomized, controlled trials (RCTs) are the gold standard for determining treatment efficacy, they do not capture the effectiveness of treatment during real-world use. We aimed to evaluate the association between demographics and multiple sclerosis (MS) disease-modi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marriott, James John, Ekuma, Okechukwu, Fransoo, Randall, Marrie, Ruth Ann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511745/ https://www.ncbi.nlm.nih.gov/pubmed/37745666 http://dx.doi.org/10.3389/fneur.2023.1243589

Ejemplares similares

Development and Internal Validation of a Disability Algorithm for Multiple Sclerosis in Administrative Data
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Development of an indicator of smoking status for people with multiple sclerosis in administrative data
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Serum neurofilament light chain in relapsing-remitting MS: Unchaining disease activity prediction?
por: Marrie, Ruth Ann
Publicado: (2017)

Good multiple sclerosis (MS) care and how to get there in Canada: Perspectives of Canadian healthcare providers working with persons with MS
por: Petrin, Julie, et al.
Publicado: (2023)

Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
por: Ng, Huah Shin, et al.
Publicado: (2022)

Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study
por: Al-Sakran, Lina, et al.
Publicado: (2019)

Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Disease-modifying drugs for multiple sclerosis and subsequent health service use
por: Ng, Huah Shin, et al.
Publicado: (2021)

Calculating and Comparing the Annualized Relapse Rate and Estimating the Confidence Interval in Relapsing Neurological Diseases
por: Akaishi, Tetsuya, et al.
Publicado: (2022)

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
por: Kowalec, Kaarina, et al.
Publicado: (2017)

Effect of Seasonal Variation on Relapse Rate in Patients With Relapsing-Remitting Multiple Sclerosis in Saudi Arabia
por: Makkawi, Seraj, et al.
Publicado: (2022)

Predicting Surgical Service Demands: A Modeling challenge using Administrative Data.
por: Katz, Alan, et al.
Publicado: (2022)

Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study
por: Fernández, Oscar, et al.
Publicado: (2020)

Relapsing and progressive MS: the sex-specific perspective
por: Rommer, Paulus Stefan, et al.
Publicado: (2020)

Performance of Regression-Based Norms for Cognitive Functioning of Persons With Multiple Sclerosis in an Independent Sample
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis
por: Kearns, Patrick K A, et al.
Publicado: (2022)

Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Attitudes of people with multiple sclerosis toward brain donation
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course
por: Huss, André, et al.
Publicado: (2020)

Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Effects of Vascular Comorbidity on Cognition in Multiple Sclerosis Are Partially Mediated by Changes in Brain Structure
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Differences in resting state functional connectivity relative to multiple sclerosis and impaired information processing speed
por: Carter, Sean L., et al.
Publicado: (2023)

Patient perspectives on switching disease-modifying therapies in the NARCOMS registry
por: Salter, Amber R, et al.
Publicado: (2014)

Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure
por: Manouchehri, Navid, et al.
Publicado: (2022)

Physical activity is related to disease severity and fatigue, but not to relapse rate in persons with relapsing remitting multiple sclerosis – a self-reported questionnaire based study
por: Schlagheck, Marit L., et al.
Publicado: (2023)

Protocol for a Cross-Sectional Study: Effects of a Multiple Sclerosis Relapse Therapy With Methylprednisolone on Offspring Neurocognitive Development and Behavior (MS-Children)
por: Kozik, Valeska, et al.
Publicado: (2022)

Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study
por: Zhang, Tingting, et al.
Publicado: (2017)

An interactive web-based programme on relapse management for people with multiple sclerosis (POWER@MS2) - development, feasibility, and pilot testing of a complex intervention
por: Wenzel, Lisa, et al.
Publicado: (2022)

Erratum: Protocol for a cross-sectional study: effects of a multiple sclerosis relapse therapy with methylprednisolone on offspring neurocognitive development and behavior (MS-children)
Publicado: (2023)

Qualitative factors shaping MS patients’ experiences of infusible disease-modifying drugs: a critical incident technique analysis
por: Larsen, Janni Lisander, et al.
Publicado: (2020)

Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis
por: Amoriello, Roberta, et al.
Publicado: (2022)

Outcome of MS relapses in the era of disease-modifying therapy
por: Stoppe, Muriel, et al.
Publicado: (2017)

Models of Care in Multiple Sclerosis: A Survey of Canadian Health Providers
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Evaluation of an interactive web-based programme on relapse management for people with multiple sclerosis (POWER@MS2): study protocol for a process evaluation accompanying a randomised controlled trial
por: Wenzel, Lisa, et al.
Publicado: (2021)

Pain and participation in social activities in people with relapsing remitting and progressive multiple sclerosis
por: Jain, Dhruv, et al.
Publicado: (2023)

The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry
por: Nickerson, Molly, et al.
Publicado: (2013)

Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience
por: Zanghì, Aurora, et al.
Publicado: (2020)

Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing–remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis
por: Lees, Samuel, et al.
Publicado: (2021)

Women's Health in Multiple Sclerosis: A Scoping Review
por: Ross, Lindsay, et al.
Publicado: (2022)

The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China
por: Zhang, Yao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ntdtc8qu73lrmkbb0243p2a3hn